The valuation assigned is $3.26 on an undiluted basis and $2.13 on a fully diluted basis. They have Melanoma & CCRCC program assumptions which are incorrect. I feel like I spent time 10 mins reading this report which I will not get back.
Dr.T - is it the 100% success potential that MST has assigned to RC220 that prompted you to send a newsletter? Apart from that, it reads like a nice fiction.
Ann: Race In-person Investor Briefing Invitation Perth, page-23
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |